Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

VBI Vaccines Inc (VBIV) NPV

Sell:$3.34 Buy:$3.37 Change: $0.16 (4.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.16 (4.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.16 (4.62%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

VBI Vaccines Inc. (VBI) is a biopharmaceutical company. VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is focused on targeting and overcoming infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). The Company’s products include 3-antigen hepatitis B virus (HBV) Vaccine Candidate; VBI-2900, which is a coronavirus vaccine program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901 GBM. The Company is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901. It is also conducting the Phase I clinical study of prophylactic COVID-19 vaccine candidate, VBI-2902 and clinical study with VBI-2905, COVID-19 vaccine candidate against the Beta variant.

Contact details

222 3rd St Ste 2241
United States
+1 (617) 8303031

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$852.51 million
Shares in issue:
256.01 million
United States
US dollar

Key personnel

  • Jeffrey Baxter
    President, Chief Executive Officer, Director
  • Christopher McNulty
    Chief Financial Officer and Head of Business Development, Director
  • David Anderson
    Chief Scientific Officer
  • Avi Mazaltov
    Global Head of Manufacturing and SciVac General Manager
  • Nell Beattie
    Chief Business Officer
  • Francisco Diazmitoma
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.